Persistent Asset Partners’s ProQR Therapeutics PRQR Stock Holding History

Persistent Asset Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$74.6K	Buy	46,067 +913	+2%	+$1.5K	0.03%	251
2025 Q4	$91.2K	Buy	45,154 +8,874	+24%	+$20.7K	0.04%	274
2025 Q3	$77.3K	Hold	36,280	–	–	0.05%	165
2025 Q2	$74K	Sell	36,280 -11,503	-24%	-$18.7K	0.05%	134
2025 Q1	$63.6K	Buy	+47,783	New	+$102K	0.05%	128

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Persistent Asset Partners's PRQR Position: Q1 2026 in Review

Persistent Asset Partners increased its ProQR Therapeutics (PRQR) stake by 2% in Q1 2026, buying an estimated $1.5K and bringing the position to 46,067 shares worth $74.6K. The position accounts for 0.03% of the portfolio, ranked #251.

Persistent Asset Partners first reported a position in PRQR in Q1 2025 and has held it in 5 quarters since. The position peaked at $91.2K in Q4 2025. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Persistent Asset Partners held 46,067 shares of ProQR Therapeutics worth $74.6K as of Q1 2026.
Persistent Asset Partners bought 913 ProQR Therapeutics shares in Q1 2026, an estimated $1.5K.
ProQR Therapeutics made up 0.03% of Persistent Asset Partners's portfolio in Q1 2026, its #251 holding.
Persistent Asset Partners first reported a position in ProQR Therapeutics in Q1 2025 and has held it in 5 quarters since.
Persistent Asset Partners's ProQR Therapeutics position peaked at $91.2K in Q4 2025.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.